DENVILLE, N.J., June 10, 2008 (PRIME NEWSWIRE) -- Lantis Laser Inc. (Pink Sheets:LLSR) (http://www.lantislaser.com), announced today that it has commenced Phase 3 of the development cycle of its proprietary, highly advanced Optical Coherence Tomography (OCT) Dental Imaging System(tm). The OCT System is a diagnostic light-based, chairside, system that images in real-time at a resolution of up to 10 times x-ray and without any harmful radiation. It is expected to have a major impact on early diagnostics and the advancement of minimally invasive treatment once it is deployed in dental offices.
"Phase 3 development, the last phase before commercial rollout, embodies a number of significant events in the evolution of OCT for dentistry," said Stan Baron, President and CEO of Lantis. "The components of the OCT System that needed to be upgraded to meet the requirements of the fast scanning speed enabled by AXSUN Technologies swept source laser, are being readied for integration into the OCT Beta Systems. We expect to deploy the Beta Systems for clinical use in the July/August timeframe."
Phase 3 of the product development cycle also requires that the OCT System's mobile cart will be designed, that the user interface be refined and that documentation in preparation for the FDA filing be prepared. After an extensive review of product design companies, Lantis is pleased to announce that it has selected Eclipse Product Development to undertake this demanding task.
Doug Hamilton, Vice President Research and Development at Lantis, commented, "OCT is not a modality that many companies have had experience with, so we looked for a company that had a solid industrial design core and the network to bring in the best available resources for each discipline that is deployed in the OCT System. Eclipse provides us with this development model and the flexibility we need to complete this Phase in an efficient and timely manner."
"All the components leading to up to FDA submission, manufacturing and marketing are now being put into place," said Baron. "We will be making regular announcements as we progress to keep the investment and dental community abreast of developments."
About Lantis Laser
Lantis was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently entering Phase 3 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System(tm) in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); Lightlab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser (Pink Sheets:LLSR), visit www.lantislaser.com
About Eclipse Product Development
Eclipse, located in Amesbury, MA has over 13 years of experience helping clients commercialize medical, laboratory and dental category technologies. The company is medically oriented and has designed numerous products including complex diagnostic and therapeutic medical and dental equipment and devices. Their development process meets FDA and ISO requirements for design control documentation and verification. Eclipse has developed a strategic business model to include several experienced molding and manufacturing vendor relationships.
Safe Harbor: Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The company intends that such statements about the Company's future expectations, including future revenues and earnings, technology efficacy and all other forward-looking statements be subject to the safe harbors created thereby. The Company is a development stage company who continues to be dependent upon outside capital to sustain its existence. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.